Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Carcinoma × futuximab × Clear all

Phase

Phase 3 1 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 2 Neoplasm Metastasis 1 Carcinoma 1

Interventions

Carboplatin 15 Cisplatin 12 Paclitaxel 11 Pemetrexed 10 pembrolizumab 9 Gemcitabine 7 Docetaxel 6 durvalumab 4 Sorafenib 4 130-nm albumin-bound paclitaxel 4 osimertinib 3 cabozantinib 3 Taxes 3 Radiotherapy 3 Mitomycin 3 Magnetic Resonance Spectroscopy 3 Cetuximab 3 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 3 trifluridine tipiracil drug combination 2 regorafenib 2 padeliporfin 2 olaparib 2 atezolizumab 2 Sunitinib 2 Specimen Handling 2 Radiotherapy, Intensity-Modulated 2 Radiation 2 Nivolumab 2 Irinotecan 2 Everolimus 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03717038 2019-02-04

Sym004 Versus TAS-102 in Patients With mCRC

Symphogen A/S

Phase 3 Withdrawn

Gastrointestinal

Carcinoma, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡